Login to Your Account



Clinic Roundup


Tuesday, March 15, 2011
StemCells Inc., of Palo Alto, Calif., started a Phase I/II trial of its HuCNS-SC human neural stem cells in chronic spinal cord injury in patients with both complete and incomplete degrees of paralysis who are three months to 12 months post-injury. The study will enroll 12 patients in three cohorts with thoracic spinal cord injuries who have a neurological injury level of T2-T11.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription